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EXPERIMENTAL
RESULTS AND DISCUSSION
CONCLUSIONS
DruQuaR
 Sample preparation development (spiked plcaebo) :
1. Placket Burman design (PBD):
HPβCD (0-10 mg/ml), temperature (50-70°C), incubation time (1-2 h),
number of steps (1-2), mixing velocity (300-600 rpm), concentration FA (1-5 % V/V).
=> FA and temperature have a significant influence (p < 0.05), BUT: too low recoveries
2. Onion design (with change FA to TFA):
Temperature (20-70°C), incubation time (30-90 min), concentration TFA (0.1-0.75 % V/V)
=> Concentration TFA significant (p < 0.05), others regional (p < 0.10)
3. Verification robustness with PBD:
Temperature (50-60°C), incubation time (40-50 min),concentration TFA (0.45-0.65 % V/V)
=> Incubation temperature significant influence hence: range ± 2°C
 HPLC-UV :
Variables optimised with PBD: acid (TFA vs FA), column temperature, ACN gradient slope
 HPLC-MS analysis for determination of related substances :
Evaluation using ESI-iontrap MS (SIM), with selectivity optimised gradient FA
 Optimised sample preparation obtained with Plackett-Burman and Onion designs: 0.45% V/V TFA at 60°C during 40 minutes
accuracy (recovery) = 97.37%, precision = 3.34%
 HPLC-UV assay characterisation .
 A selective method for specified related substances profiling for nasal powder was established, using HPLC-ESI/MS (SIM).
Calcitonin is a 32-amino acid polypeptide hormone ubiquitous in humans and animals. It acts i.a. to reduce blood calcium (Ca2+), opposing the effects of
parathyroid hormone (PTH). Both human (hu) and salmon (sa) calcitonins are clinically effective and currently approved as active pharmaceutical
ingredients (APIs).
A new bioadhesive nasal formulation is currently under development, which contains low dose sa-calcitonin in polymeric excipients (carbomer and starch).
The analytical development is confronted with several challenges: the low dose of the peptide in the formulation, its inherent instability, the polymeric matrix
interacting with the peptide influencing sample preparation and its undefined degradation impurity profile in this formulation.
The aim of this investigation was to develop a suitable method to determine the concentration of sa-calcitonin in this formulation and to establish its
degradation profile, using experimental designs which will also give us mechanistic information.
 The final HPLC conditions for the assay are listed in Table 1, while a typical chromatogram of the selecivity study for related compounds is given in Figure 2
Figure 1: 3D visualisation of the Onion design
Figure 2: HPLC-MS for related substancesTable 1: HPLC method for sa-calcitonin assay
Parameter Specification
Column Everest C18 (300 Å), 250 × 4.6 mm, 5 µm (+ guard column)
Column temperature 40°C
Mobile phase
- Solvent A: 0.1% V/V TFA in water.
- Solvent B: 0.085% V/V TFA in acetonitrille.
Gradiënt programme
Time (min)
Solvent constitution with TFA
%A %B
0 73 27
20 63 37
21 73 27
40 73 27
Flow 1 ml/min
Injection volume 100 µl
Detection UV at 195 nm
Peak identification RRT m/Z
1: cys-ser hydrolysis product 0.5 862.81-863.81
2: calcitonin trisulfide 0.9 866.30-876-30
3:  sa-calcitonin 1.00 859.37-860-49
4:  epimer 1.25 859.37-860-49
5: acetylated calcitonin 1.50 868.81-869.81
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Table 2: Peak identification corresponding to Figure 2
